Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
In this case study, Dr. Papasavva describes her laboratory’s journey from traditional thalassemia testing to state-of-the-art NGS technology and what a difference this has made in their daily work.
Whitepaper
This whitepaper explores the diagnostic
challenges posed by the α3.7 and α4.2 deletions in
alpha thalassemia testing and the opportunities to
overcome the limitations of traditional methods.
In this whitepaper, you will learn:
• The molecular basis and clinical implications of the
α3.7 and α4.2 deletions.
• Key challenges in the detection of these deletions
using traditional diagnostic methods.
• Advances in NGS technologies and their impact on
thalassemia diagnostics.
• The need for integrated data analysis software to
enable accessibility to thalassemia genetic testing.
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More